Definium Therapeutics, Inc. Common Shares Share Price
NASDAQ: DFTX
Live Definium Therapeutics, Inc. Common Shares Share Price Chart
O H L
Definium Therapeutics, Inc. Common Shares Performance Overview
Days Range
▼
$38.15Low
$38.80High
Markets Today
| Previous Close | $38.68 |
|---|---|
| Open | $38.50 |
| Volume | 186,318 |
| Day's Range | $38.15 - $38.80 |
| 52W Range | NA |
| Market Cap | $5.09 B |
Historical Performance
| 1M Returns | -16.24 |
|---|---|
| 3M Returns | +58.01 |
| 6M Returns | +119.27 |
| 1Y Returns | NA |
| 5Y Returns | NA |
| 10Y Returns | NA |
Definium Therapeutics, Inc. Common Shares Fundamentals
| Market Cap | $5.09 B |
|---|---|
| Dividend yield | N/A |
| PE Ratio | N/A |
| PEG Ratio | N/A |
| Revenue | N/A |
| ROE TTM | N/A |
| EPS TTM | N/A |
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | N/A |
| EBITDA | N/A |
| Profit Margin | N/A |
| Market Cap | $5.09 B |
|---|---|
| Dividend yield | N/A |
| PE Ratio | N/A |
| PEG Ratio | N/A |
| Revenue | N/A |
| ROE TTM | N/A |
| EPS TTM | N/A |
|---|---|
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | N/A |
| EBITDA | N/A |
| Profit Margin | N/A |
Definium Therapeutics, Inc. Common Shares Profit & Loss
Quarterly
| Mar 2026 | Jun 2026 | |
|---|---|---|
| Total Revenue + | $0 | $0 |
| Gross Profit + | $0 | $0 |
| Operating Income | -$59.22 M | -$75.08 M |
| EBITDA | -$59.22 M | -$75.08 M |
| Interest Expense | -$1.25 M | -$1.23 M |
| Depreciation | $0 | $0 |
| Income Before Tax | -$77.10 M | -$158.99 M |
| Income Tax Expense | $0 | $0 |
| Net Income + | -$77.10 M | -$158.99 M |
| Net Profit Margin | - | - |
Definium Therapeutics, Inc. Common Shares Financials Balance Sheet In USD
Quarterly
| Mar 2026 | Jun 2026 | |
|---|---|---|
| Share Capital | $0 | $0 |
| Reserve & Surplus | -$658.95 M | -$818.34 M |
| Non-Current Liabilities | $41.33 M | $37.02 M |
| Current Liabilities | $81.11 M | $157.20 M |
| Total Liabilities | $122.44 M | $194.22 M |
| Fixed Assets | $0 | $0 |
| Current Assets | $380.56 M | $1.09 B |
| Total Assets | $401.29 M | $1.11 B |
Definium Therapeutics, Inc. Common Shares Cash Flow
Quarterly
| Mar 2026 | Jun 2026 | |
|---|---|---|
| Net Income | -$77.10 M | -$158.99 M |
| Operating Cash Flow | -$42.63 M | -$52.78 M |
| Investing Cash Flow | $42.00 M | -$316.74 M |
| Financing Cash Flow | $5.31 M | $762.27 M |
| Change in Cash | $4.68 M | $392.75 M |
Definium Therapeutics, Inc. Common Shares Return Calculator
The Definium Therapeutics, Inc. Common Shares stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Returns Estimator
Based on past performance of this fund
ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$10,000
Invested Amount$10,000
Est. Returns$0
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Popular Stocks
FAQs
What is the share price of Definium Therapeutics, Inc. Common Shares today?
Definium Therapeutics, Inc. Common Shares (DFTX) share price as of September 18, 2026 is $38.02. If you are investing from India, you can always check the valuation in the INR before investing.
Can Indian Investors purchase shares of Definium Therapeutics, Inc. Common Shares?
Yes, Indian Investors can invest in the Definium Therapeutics, Inc. Common Shares (DFTX) Share by opening an international trading account with Angel One.
How can I purchase Definium Therapeutics, Inc. Common Shares shares in India?
Purchasing Definium Therapeutics, Inc. Common Shares (DFTX) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Definium Therapeutics, Inc. Common Shares (DFTX) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Can I buy Fractional shares of Definium Therapeutics, Inc. Common Shares?
Yes, you can purchase fractional shares of Definium Therapeutics, Inc. Common Shares (DFTX) or any other US company shares in Angel One for any dollar amount.
What is the market capitalization value of Definium Therapeutics, Inc. Common Shares?
The market capitalization of Definium Therapeutics, Inc. Common Shares on September 18, 2026, is $5.09 B.
In which sector Definium Therapeutics, Inc. Common Shares belongs?
Definium Therapeutics, Inc. Common Shares operates in the null sector, specifically in the null industry.
What documents are required to invest in Definium Therapeutics, Inc. Common Shares stocks?
In order to invest in Definium Therapeutics, Inc. Common Shares (DFTX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.
Diversify Your Portfolio with US Stocks
Invest in Wall Street Giants from India
